Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Alessandro De Camilli
 -- 1628 2023-08-22 15:01:34 |
2 format correction
Dean Liu
Meta information modification 1628 2023-08-23 02:39:52 | |
3 format correction
Dean Liu
Meta information modification 1628 2023-08-24 03:11:41 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
De Camilli, A.; Fischer, G. Novel Cellular and Immunotherapy. Encyclopedia. Available online: https://encyclopedia.pub/entry/48329 (accessed on 06 August 2024).
De Camilli A, Fischer G. Novel Cellular and Immunotherapy. Encyclopedia. Available at: https://encyclopedia.pub/entry/48329. Accessed August 06, 2024.
De Camilli, Alessandro, Gregory Fischer. "Novel Cellular and Immunotherapy" Encyclopedia, https://encyclopedia.pub/entry/48329 (accessed August 06, 2024).
De Camilli, A., & Fischer, G. (2023, August 22). Novel Cellular and Immunotherapy. In Encyclopedia. https://encyclopedia.pub/entry/48329
De Camilli, Alessandro and Gregory Fischer. "Novel Cellular and Immunotherapy." Encyclopedia. Web. 22 August, 2023.
Novel Cellular and Immunotherapy
Edit
This entry is adapted from the peer-reviewed paper 10.3390/curroncol30080554

Targeted cellular and immunotherapies have welcomed a new chapter in multi-modal cancer therapy. These agents harness our innate immune system and destroy malignant cells in a precise way as compared with “legacy” chemotherapeutic agents that largely rely on abolishing cell division. New therapies can augment the T-cell recognition of tumor antigens and effectively prevent tumor cells from their historically successful ability to evade immune recognition. These novel agents cause acute and chronic toxicities to a variety of organ systems (enteritis, pneumonitis, hypophysitis, and hepatitis), and this may masquerade as other chronic illnesses or paraneoplastic effects. As the perioperative footprint of cancer patients increases, it is essential that perioperative providers—anesthesiologists, surgeons, nurse anesthetists, and inpatient hospital medicine providers—be up to date on the physiologic mechanisms that underlie these new therapies as well as their acute and subacute toxicity profiles. Immunotherapy toxicity can significantly impact perioperative morbidity as well as influence perioperative management, such as prophylaxis for adrenal insufficiency, preoperative pulmonary assessment, and screening for thyroid dysfunction, among others.

immunotherapy cellular therapy perioperative risk hypophysitis

1. Introduction

The last decade has brought about a revolution in cancer therapies that harness the immune system to target cancer-specific antigens. These agents were once reserved for use in palliative chemotherapy for patients with unresectable or refractory metastatic disease. They have now firmly established their intention-to-cure role and play a significant role in neo-adjuvant therapy [1][2][3][4][5][6][7][8][9][10][11][12][13]. Immunotherapies have greatly improved quality of life for patients with advanced cancer. More than ever, it is necessary for the perioperative provider to be up to date on the physiology underlying these therapies as well as their unique toxicity profiles.
Early-generation chemotherapeutics relied on nonspecific destruction of cell division, with toxicities mostly related to en masse destruction of rapidly dividing cells. Newer immunotherapies have a more benign acute safety profile but nonetheless can exert chronic toxicities that may be more insidious and require a higher index of suspicion for detection. The predominant cause of toxicities results from unwanted upregulated immune system activity or molecular mimicry, leading to destruction of “bystander” tissue.
To provide an example, ipilumumab and nivolumab are two immune-checkpoint inhibitors (ICIs) that have recently been shown to improve survival when included as part of neoadjuvant therapy for squamous cell esophageal cancer [14]. However, the two drugs in combination can lead to a non-negligible incidence of ICI pneumonitis and ICI hypophysitis. It is thus becoming more important for thoracic surgeons and anesthesiologists who care for these patients to be aware of the potential risks of adrenal insufficiency and reduced pulmonary capacity. A thorough therapeutic history and close collaboration with oncologists are necessary to provide safe care.

2. Immune-Checkpoint Inhibitors

Immune-checkpoint inhibitors have earned their keep as tremendously successful adjuncts to all manner of chemotherapeutic regimens. The innate immune system relies on T-cell activation and proliferation to destroy foreign cells. T-cell activation requires both antigen–receptor coupling as well as co-stimulation by other immune effectors cells. This two-fold process underpins the versatility of the immune system but is also the process by which cancer cells can evade detection. T-cell activation can be inhibited by two pathways: the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) pathway and the programmed cell death protein (PD-LA1) pathway. This interplay of T-cell activation and inhibition is referred to as an “immune checkpoint.”
Cancer cells have evolved to thwart T-cell activation by taking advantage of the inhibition role of this immune checkpoint since CTLA-4 and PD-LA1 antigens are commonly found on the surfaces of tumor cells. Activation of these ligands by tumor cells allows them to evade detection.
Immune-checkpoint inhibitors (ICIs), as a therapeutic target, prevent tumor cell evasion by acting as monoclonal antibodies against the CTLA-4 and PD-LA1 ligands. In preventing their ability to inactivate T cells, ICIs ensure that tumor cells are vulnerable to destruction (see Figure 1).
Curroncol 30 00554 g001 550
Figure 1. Above: normal immune checkpoint activity means that cancer (as tumor cells directly or as tumor antigen presented via an APC) can inhibit T-cell activation via the CTLA-4 and PD-1 ligands. Below: immune checkpoint inhibitors prevent this inhibition, leading to T-cell activation.
This has proven to be a very effective therapeutic target, with successes in the treatment of melanoma, breast cancer, and lymphoma, to name a few.
Checkpoint inhibition technology has continued to advance as new agents are developed that target additional T-cell pathways and as existing ones are used on new tumor subtypes.
The first immune-checkpoint inhibitors approved for human use were Ipilimumab and Nivolumab (2011 and 2014, respectively). Ipilimumab acts as a monoclonal antibody against CTLA-4 and Nivolumab against PD-1. Ipilimumab was initially shown to dramatically improve survival in patients with metastatic melanoma [15]. The subsequent arrival of Nivolumab showed promise for the two used as combination therapy both for metastatic melanoma and several other cancers—renal cell carcinoma, unresectable non-small-cell lung cancer (NSCL), prostate cancer, and esophageal cancer [15][16].
Immune-checkpoint inhibitors have shown promise in treating tumors that have been historically resistant to other chemo or immunotherapeutic agents, but there are highly specific indications for the use of each. Up to 45% of patients with cancer are candidates for ICI therapy [17], so the perioperative footprint of these patients continues to rise. Their efficacy is determined by the rate of target PD-L1 or CTLA-4 receptor expression on the tumor cells, the mutational burden of tumors, and the relative inefficacy of classic chemotherapy agents for the tumor in question.
ICI therapy in the perioperative period is an area of ongoing study. Thus far, a few studies at major cancer centers have shown no association with perioperative morbidity of any type [18], and in fact, most show greatly improved results when added as neo-adjuvant therapy [9][10][11].

3. Chimeric Antigen-Receptor T Cells (CAR-T)

CAR-T cells harness the adaptive immunity offered by the T-lymphocytes to target tumor-specific antigens. As the first foray into cellular therapeutics, they represent one of the most consequential discoveries in cancer therapy in the last two decades owing to their relative ease of administration and robust efficacy against highly fatal hematologic malignancies. As discussed in the previous section, the immune system relies on T-cell activation via (1) antigen presentation via an MHC complex and (2) co-stimulation via other immune effector cells. Cancer cells have historically evaded this process of T-cell activation by thwarting antigen recognition. Enter CAR-T cells: the genetically modified host T cells that force this process to occur without the ability of tumor-cell evasion.
First, T cells are extracted from the patient (or an allogeneic donor) and modified via a retroviral vector to express a new antigen receptor and co-stimulatory domains (see Figure 2). The term “chimeric” refers to the fact that this engineered receptor both activates and co-stimulates the T cell [19][20]. The patient is then leuko-reduced to increase the relative proportion of CAR-T cells, and CAR-T cells are infused into the patient. The CAR-T cells will recognize antigens and activate and recruit immune effector cells to destroy tumor cells.
Curroncol 30 00554 g002a 550Curroncol 30 00554 g002b 550
Figure 2. Above: normal T-cell activation requires antigen recognition and co-stimulation. Below: a re-engineered CAR-T cell enables simultaneous antigen recognition and co-stimulation, leading to T-cell-mediated destruction of tumor cells.
The first CAR-T cells used clinically targeted the CD19 receptor, making them effective for the treatment of ALL or diffuse large B-cell lymphoma [21]. Trials have consistently shown a 50–90% remission rate for relapsed or refractory disease, which continues to improve with refinement of technique [22]. CAR-T for solid tumors is a growing area of research, where re-modeled CAR-T cells can be introduced intra-tumorally or intra-pleurally [23].
Once infused, CAR-T cell activity can be controlled via embedded biochemical switches. An “on” switch or, conversely, a “suicide gene” can induce CAR-T cell activation or apoptosis. These external controls allow CAR-T technology to be more pliable in the face of toxicities or other adverse events.

4. Bispecific T-Cell Engager (BiTE) Therapy

BiTE therapy is one of the newest innovations in targeted immunomodulatory chemotherapy. BiTE molecules are an antibody with two domains (hence “bispecific”): one that recognizes tumor-specific antigens and another that recognizes the universal CD-3 receptor on T cells (see Figure 3). The binding sites are essentially two monoclonal antibodies bound together. In essence, the BiTE “forces” a recognition and activation of the T cell, so the tumor cell does not have a chance to present its own antigen and possibly release inhibitory signal receptors. Specific tumor antigen targets of BiTE molecules include CD19 (broadly expressed on B-cell malignancies), B-cell maturation antigen (expressed highly on malignant cells involved in multiple myeloma), and CD33 (expressed in acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia). Under development are BiTE targets that include solid tumor antigens such as prostate-specific member antigen and delta-like protein 3, which is highly prevalent in small-cell lung cancer.
Curroncol 30 00554 g003 550
Figure 3. The Bispecific T-cell engager (BiTE) molecule has shown promise as a targeted immunotherapy but, unlike CAR-T, does not require harvesting of the patient’s native lymphocytes.
The most widely used BiTE agent at this time is Blinatumomab, approved for use in acute lymphoblastic leukemia (ALL). Trial response rates in children and adults with ALL have shown a resounding 90% complete remission rate, with a 6-month event-free survival of 67% and a 78% overall survival rate [24]. It is now approved for use around the globe. Solitumab is a BiTE molecule with a binding domain for the epithelial cell adhesion molecule (EpCAM), which is being investigated for therapy against gastrointestinal, lung, and other solid tumors [25].
These molecules are administered as continuous IV infusion over several days owing to their 2–4-h half-life. Not unsurprisingly, owing to their similar mechanisms, they have an adverse event profile that parallels that of CAR-T cells. In the original study for Blinatumomab, the most common adverse events were neutropenia, infection, elevated LFTs, neurotoxicity, and CRS [26]. CRS, neurotoxicity, and acute anaphylaxis are the most significant for the acute care and perioperative provider. There is perhaps a lower propensity than CAR-T for high-grade neurotoxicity [27]. Treatment for these adverse events follows the same protocol: corticosteroids, IL-6 inhibition, and supportive care.

References

  1. Forde, P.M.; Spicer, J.; Lu, S.; Provencio, M.; Mitsudomi, T.; Awad, M.M.; Felip, E.; Broderick, S.R.; Brahmer, J.R.; Swanson, S.J.; et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N. Engl. J. Med. 2022, 386, 1973–1985.
  2. Cascone, T.; William, W.N., Jr.; Weissferdt, A.; Leung, C.H.; Lin, H.Y.; Pataer, A.; Godoy, M.C.B.; Carter, B.W.; Federico, L.; Reuben, A.; et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nat. Med. 2021, 27, 504–514.
  3. Mays, A.C.; Yarlagadda, B.; Achim, V.; Jackson, R.; Pipkorn, P.; Huang, A.T.; Rajasekaran, K.; Sridharan, S.; Rosko, A.J.; Orosco, R.K.; et al. Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer. Head Neck 2021, 43, 1509–1520.
  4. Weber, J.S.; Kähler, K.C.; Hauschild, A. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. J. Clin. Oncol. 2012, 30, 2691–2697.
  5. Wolchok, J.D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.-J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Schadendorf, D.; Ferrucci, P.F.; et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2017, 377, 1345–1356, Erratum in N. Engl. J. Med. 2018, 379, 2185.
  6. Ikeuchi, K.; Okuma, Y.; Tabata, T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. Lung Cancer 2016, 99, 148–150.
  7. Thompson, J.A.; Schneider, B.J.; Brahmer, J.; Achufusi, A.; Armand, P.; Berkenstock, M.K.; Bhatia, S.; Budde, L.E.; Chokshi, S.; Davies, M.; et al. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2022, 20, 387–405.
  8. Nishimura, H.; Okazaki, T.; Tanaka, Y.; Nakatani, K.; Hara, M.; Matsumori, A.; Sasayama, S.; Mizoguchi, A.; Hiai, H.; Minato, N.; et al. Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice. Science 2001, 291, 319–322.
  9. Bonaca Marc, P.; Olenchock, B.A.; Salem, J.-E.; Wiviott, S.D.; Ederhy, S.; Cohen, A.; Stewart, G.C.; Choueiri, T.K.; Di Carli, M.; Allenbach, Y.; et al. Myocarditis in the setting of cancer therapeutics. Circulation 2019, 140, 80–91.
  10. Cui, K.; Wang, Z.; Zhang, Q.; Zhang, X. Immune checkpoint inhibitors and adrenal insufficiency: A large-sample case series study. Ann. Transl. Med. 2022, 10, 251.
  11. Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N. Engl. J. Med. 2010, 363, 711–723, Erratum in N. Engl. J. Med. 2010, 363, 1290.
  12. Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer J. 2016, 22, 117–120.
  13. Data Presented at AACR Support Potential of Peregrine’s PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer. Reuters. Archived from the Original on 2014-05-21. Available online: https://www.biospace.com/article/releases/data-presented-at-american-association-for-cancer-research-support-potential-of-peregrine-pharmaceuticals-inc-s-ps-targeting-immunotherapy-bavituxim/ (accessed on 1 August 2023).
  14. Doki, Y.; Ajani, J.A.; Kato, K.; Xu, J.; Wyrwicz, L.; Motoyama, S.; Ogata, T.; Kawakami, H.; Hsu, C.-H.; Adenis, A.; et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N. Engl. J. Med. 2022, 386, 449–462.
  15. Opdivo-Nivolumab Injection. DailyMed. 17 December 2019. Available online: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394 (accessed on 11 March 2020).
  16. Hellmann, M.D.; Paz-Ares, L.; Bernabe Caro, R.; Zurawski, B.; Kim, S.-W.; Carcereny Costa, E.; Park, K.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; et al. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2019, 381, 2020–2031.
  17. Haslam, A.; Gill, J.; Prasad, V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Netw. Open 2020, 3, e200423.
  18. Elias, A.W.; Kasi, P.M.; Stauffer, J.A.; Thiel, D.D.; Colibaseanu, D.T.; Mody, K.; Joseph, R.W.; Bagaria, S.P. The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. Front. Oncol. 2017, 7, 121.
  19. Zhang, H.; Zhao, P.; Huang, H. Engineering better chimeric antigen receptor T cells. Exp. Hematol. Oncol. 2020, 9, 34.
  20. Kochenderfer, J.N.; Wilson, W.H.; Janik, J.E.; Dudley, M.E.; Stetler-Stevenson, M.; Feldman, S.A.; Maric, I.; Raffeld, M.; Nathan, D.-A.N.; Lanier, B.J.; et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116, 4099–4102.
  21. Zhang, X.; Lu, X.-A.; Yang, J.; Zhang, G.; Li, J.; Song, L.; Su, Y.; Shi, Y.; Zhang, M.; He, J.; et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020, 4, 2325–2338.
  22. Kyte, J.A. Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers. Cancers 2022, 14, 571.
  23. Maude, S.L.; Frey, N.; Shaw, P.A.; Aplenc, R.; Barrett, D.M.; Bunin, N.J.; Chew, A.; Gonzalez, V.E.; Zheng, Z.; Lacey, S.F.; et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014, 371, 1507–1517.
  24. Helwick, C. Novel BiTE antibody mediates contact between T cells and cancer cells. Oncol. NEWS Int. 2008, 17.
  25. Dombret, H.; Topp, M.S.; Schuh, A.C.; Wei, A.H.; Durrant, S.; Bacon, C.L.; Tran, Q.; Zimmerman, Z.; Kantarjian, H. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk. Lymphoma 2019, 60, 2214–2222.
  26. Diefenbach, C.; Assouline, S.; Bosch, F.; Cheah, C.Y.; Kim, W.S.; Matasar, M.J.; Panizo, C.; Yoon, D.H.; Bender, B.; Hernandez, G.; et al. An individualized risk mitigation approach for safety: Experience from the mo-sunetuzumab (CD20/CD3 bispecific antibody) development program in relation to neurotoxicity risk . Blood 2019, 134 (Suppl. S1), 4728.
  27. Lee, D.W.; Santomasso, B.D.; Locke, F.L.; Ghobadi, A.; Turtle, C.J.; Brudno, J.N.; Maus, M.V.; Park, J.H.; Mead, E.; Pavletic, S.; et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol. Blood Marrow Transplant. 2019, 25, 625–638.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Anesthesiology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Alessandro De Camilli
,
Gregory Fischer
View Times: 211
Revisions: 3 times (View History)
Update Date: 24 Aug 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback